Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing

    Access Status
    Fulltext not available
    Authors
    van der Vlugt, M.
    Grobbee, E.
    Bossuyt, P.
    Bos, A.
    Bongers, E.
    Spijker, W.
    Kuipers, E.
    Lansdorp_Vogelaar, Iris
    Spaander, M.
    Dekker, E.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    van der Vlugt, M. and Grobbee, E. and Bossuyt, P. and Bos, A. and Bongers, E. and Spijker, W. and Kuipers, E. et al. 2017. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. Gastroenterology. 153 (2): pp. 439-447.e2.
    Source Title
    Gastroenterology
    DOI
    10.1053/j.gastro.2017.05.004
    ISSN
    0016-5085
    School
    Centre for Behavioural Research in Cancer Control
    URI
    http://hdl.handle.net/20.500.11937/56033
    Collection
    • Curtin Research Publications
    Abstract

    © 2017 AGA Institute Background & Aims Among subjects screened for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of the subjects. Data are limited on how many persons screened by fecal immunochemical tests (FIT), over multiple rounds, develop interval cancers. In the Netherlands, a pilot FIT-based biennial CRC screening program was conducted between 2006 and 2014. We collected and analyzed data from the program on CRCs detected during screening (SD-CRC) and CRCs not detected within the screening program (non–SD-CRC; such as FIT interval cancers, colonoscopy interval cancers, and cancer in nonparticipants). Methods Screenees with a negative FIT result received a letter explaining that no blood had been detected in the stool sample and were re-invited, if eligible, for screening biennially. Screenees with a positive FIT result (hemoglobin concentration of 10 µg Hb/g feces) were invited for consultation and scheduled for colonoscopy; results were collected. After the fourth round of FIT screening, the cohort was linked to the Netherlands Cancer Registry, through March 31, 2015; participant characteristics, data on tumor stage, location (at time of resection), and survival status were collected for all identified CRC cases. A reference group comprised all persons with CRC diagnosed in the Netherlands general population during the same period, in the same age range (50–76 years), who had not been offered CRC screening. The median time between invitations (2.37 years) was used as a cutoff to categorize participants within the FIT interval cancer category. We compared participant characteristics, tumor characteristics, and mortality among subjects with SD-CRC and with non–SD-CRC. Results A total of 27,304 eligible individuals were invited for FIT screening, of whom 18,716 (69%) participated at least once. Of these, 3005 (16%) had a positive result from the FIT in 1 of the 4 screening rounds. In total, CRC was detected in 261 participants: 116 SD-CRCs and 145 non–SD-CRCs (27 FIT interval cancers, 9 colonoscopy interval cancers, and 109 CRCs in nonparticipants). The FIT interval cancer proportion after 3 completed screening rounds was 23%. Participants with SD-CRC had more early-stage tumors than participants with non–SD-CRCs (P < .001). Of persons with SD-CRC and FIT interval cancers, significantly higher proportions survived (89% and 81%, respectively) compared with persons with colonoscopy interval cancers (44% survival) and nonparticipants with CRC (60% survival) (P < .001). Conclusions In an analysis of data from a pilot FIT-based biennial screening program, we found that among persons screened by FIT, 23% developed FIT interval cancer. FIT therefore detects CRC with 77% sensitivity. The proportion of FIT interval cancers in FIT screening appears to be lower than that with guaiac fecal occult blood testing. Clinical trial registry: yes, www.trialregister.nl, trial number: NTR5385.

    Related items

    Showing items related by title, author, creator and subject.

    • Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program
      Wieten, E.; Schreuders, E.; Nieuwenburg, S.; Hansen, B.; Lansdorp_Vogelaar, Iris; Kuipers, E.; Bruno, M.; Spaander, M. (2016)
      Background & Aims: Several countries have implemented programs to screen for colorectal cancer (CRC) by using the fecal immunochemical test (FIT). These programs vary considerably in age of the population screened and the ...
    • Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia
      Kapidzic, A.; van der Meulen, M.; Hol, L.; van Roon, A.; Looman, C.; Lansdorp_Vogelaar, Iris; van Ballegooijen, M.; van Vuuren, A.; Reijerink, J.; van Leerdam, M.; Kuipers, E. (2015)
      Background & Aims: Fecal immunochemical tests (FITs) are used widely in colorectal cancer screening. Programs use the same fecal hemoglobin threshold for colonoscopy referral for men and women, but it is unclear whether ...
    • Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening
      Grobbee, E.; Kapidzic, A.; van Vuuren, A.; van Leerdam, M.; Lansdorp-Vogelaar, Iris; Looman, C.; Bruno, M.; Kuipers, E.; Spaander, M. (2015)
      Objectives: Fecal immunochemical testing (FIT) and colonoscopy are tandem procedures in colorectal cancer (CRC) screening. A positive FIT predicts advanced neoplasia (AN) that requires endoscopic detection and removal. ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.